ABOVE: © ISTOCK.COM, YACOBCHUKOLENA
Update (April 21, 2022): In research published today in JAMA Network Open, C2N Diagnostics scientists and their colleagues report that the company’s blood test had an overall accuracy of 81 percent in predicting whether adults with cognitive impairment would show amyloid plaques on a PET scan.
The first blood test designed to assist physicians in determining whether a patient has Alzheimer’s disease is now available in most US states, the company C2N Diagnostics announced October 29. The test measures biomarkers that frequently reflect the presence of amyloid plaques in the brain—a hallmark of Alzheimer’s—as well as the presence of a gene variant that increases the risk of the disease.
“I’m very excited about it,” says Suzanne Schindler, a neurologist at the Washington University School of Medicine in St. Louis who was involved in testing an earlier version of the assay but is not connected to C2N. ...
